Combinational Diuretics in Heart Failure

Curr Heart Fail Rep. 2024 Aug;21(4):1-11. doi: 10.1007/s11897-024-00659-9. Epub 2024 Apr 9.

Abstract

Purpose of review: Diuretics are the cornerstone therapy for acute heart failure (HF) and congestion. Patients chronically exposed to loop diuretics may develop diuretic resistance as a consequence of nephron remodelling, and the combination of diuretics will be necessary to improve diuretic response and achieve decongestion. This review integrates data from recent research and offers a practical approach to current pharmacologic therapies to manage congestion in HF with a focus on combinational therapy.

Recent findings: Until recently, combined diuretic treatment was based on observational studies and expert opinion. Recent evidence from clinical trials has shown that combined diuretic treatment can be started earlier without escalating the doses of loop diuretics with an adequate safety profile. Diuretic combination is a promising strategy for overcoming diuretic resistance in HF. Further studies aiming to get more insights into the pathophysiology of diuretic resistance and large clinical trials confirming the safety and efficacy over standard diuretics regimens are warranted.

Keywords: Acetazolamide; Diuretics; Furosemide; Heart failure; Spironolactone; Thiazides.

Publication types

  • Review

MeSH terms

  • Diuretics* / administration & dosage
  • Diuretics* / therapeutic use
  • Drug Therapy, Combination*
  • Heart Failure* / drug therapy
  • Heart Failure* / physiopathology
  • Humans
  • Sodium Potassium Chloride Symporter Inhibitors / administration & dosage
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use

Substances

  • Diuretics
  • Sodium Potassium Chloride Symporter Inhibitors